SCHEMBL2921882

SCHEMBL2921882

OC(Cc1ccccc1)(Cc1ccccc1)C1CNCCO1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 14/20 0.72
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
ADRB2 P07550 1/20 0.36
HTR1A P08908 1/20 0.36
HTR2A P28223 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
ADRA2C P18825 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14203047 0.84 SLC6A2 (1.00) SLC6A2DRD2DRD3SLC6A4SLC6A3
SCHEMBL14202964 0.84 SLC6A2 (1.00) SLC6A2DRD2DRD3SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL5038409 0.83 SLC6A2 (0.97) SLC6A2SLC6A4HTR1ACYP2D6CYP1A2
Hydrochloric Acid SCHEMBL5038412 0.83 SLC6A2 (0.97) SLC6A2SLC6A4HTR1ACYP2D6CYP1A2
Hydrochloric Acid SCHEMBL5433451 0.83 SLC6A2 (0.97) SLC6A2SLC6A4HTR1ACYP2D6CYP1A2
SCHEMBL2919908 0.77 SLC6A2 (0.75) SLC6A2SLC6A4SLC6A3ADRB2HTR1A
Hydrochloric Acid SCHEMBL2912037 0.76 SLC6A2 (0.76) SLC6A2SLC6A4SLC6A3ADRB2HTR1A
SCHEMBL28233543 0.75 SLC6A2 (0.56) SLC6A2SLC6A4
SCHEMBL18284760 0.75 SLC6A2 (0.63) SLC6A2DRD2DRD3SLC6A4SLC6A3
SCHEMBL2904963 0.74 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2223916-A1 Morpholine derivatives as norepinephrine reuptake inhibitors Eli Lilly and Company (US) 2010-09-01 EP disclosed
US-7423037-B2 e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator ELI LILLY AND COMPANY (US) 2008-09-09 US disclosed
US-20070083046-A1 Morpholine derivatives as norepinephrine reuptake inhibitors ELI LILLY AND COMPANY (US) 2007-04-12 US disclosed
EP-1682523-A1 MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2006-07-26 EP disclosed
WO-2005047272-A1 MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070083046-A1 Morpholine derivatives as norepinephrine reuptake inhibitors SLC6A2, SLC18A2, SLC6A3 SLC6A2 1/4885DRD2 38/4885DRD3 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.